Biorasi

Biorasi Biorasi is a global clinical research organization (CRO) that delivers speed-to-market strategies for small to midsized biotech and biopharma sponsors.

Biorasi is a customer-focused, full-service, contract research organization (CRO) that delivers fast and flexible solutions across global clinical trials to maximize speed-to-market for its sponsors. As the leader in neurology, nephrology, dermatology, and the rare disease market, Biorasi sets new standards for speed, agility, and quality in patient enrollment, decentralized trials, and data transparency. It is Biorasi’s mission to be a catalyst for growth, innovation, and evolution in the field of clinical research – moving the industry forward while improving results for our partners and outcomes for their patients. Our culture is based on our strong commitment to building true partnerships with our sponsors. We approach all of our trials with urgency, commitment, and resolve. Established in 2002, Biorasi is headquartered in Aventura, FL, with office-based teams around the globe. From its regional presences, Biorasi is able to directly support studies in the Americas, Europe, and APAC. We have received multiple accolades including placement in the INC 500 and 5000 list of fastest-growing companies in America, Frost and Sullivan’s Entrepreneurial Company of the Year for the CRO Industry, and the CRO Leadership Award from Life Science Leader magazine.

10/08/2025

"What they don’t do is anything to increase activation of Tregs and Bregs that naturally react to and shut down inflammation."

How do you control an inflammatory cascade? Find out in our latest episode of the Biorasi Few & Far Between podcast. Host Chris O'Brien welcomes Woody Bryan, President and CEO at Revolo Biotherapeutics.

Tune in today! Find this episode on your favorite streaming platform or visit >> https://bit.ly/FewandFarBetween

NEWS ALERT: New Biorasi website drives reliable, flexible, and transparent solutions >> https://bit.ly/NewBiorasiWebsi...
10/08/2025

NEWS ALERT: New Biorasi website drives reliable, flexible, and transparent solutions >> https://bit.ly/NewBiorasiWebsite

ACCESS Newswire is the leading global press release distribution service. Tell your story and reach millions of journalists. Contact us today to get started.

Today’s are more than meets the eye. 👁️Behind every study is a team working collaboratively with stakeholders to dri...
10/07/2025

Today’s are more than meets the eye. 👁️

Behind every study is a team working collaboratively with stakeholders to drive enrollment, capture data, and meet critical milestones.

Meet up with Biorasi’s Nancy Newark and Rob Royall at New England this month to find out how our reliability, flexibility, and transparency deliver study results across multiple therapeutic areas – from oncology to dermatology and more.

Schedule time with our team >> https://bit.ly/ContactBiorasiToday

Why is a feather-light touch important in fighting infections?Find out in our latest episode of the Biorasi Few & Far Be...
10/01/2025

Why is a feather-light touch important in fighting infections?

Find out in our latest episode of the Biorasi Few & Far Between podcast! Host Chris O'Brien welcomes Woody Bryan, President and CEO of Revolo Biotherapeutics. Tune in as we press the reset button on the human immune system, explore upstream and downstream levers for treating autoimmune diseases, and discuss how to stay competitive in the biotech industry.

Listen today! Find this episode on your favorite streaming platform or visit >> https://lnkd.in/g2KE2SGA

Tune in tomorrow for a new episode of Biorasi's Few & Far Between podcast!Host Chris O'Brien weclomes Woody Bryan, Presi...
09/30/2025

Tune in tomorrow for a new episode of Biorasi's Few & Far Between podcast!

Host Chris O'Brien weclomes Woody Bryan, President and CEO of Revolo Biotherapeutics. Tune in as we discuss resetting the immune system, optimizing patient safety, and prioritizing both good science and good teams.

09/24/2025

"If you cannot connect AI with sensory capabilities, no amount of training will be enough."

Can reason about disease biology without access to real biology? Find out in our latest episode of the Biorasi Few & Far Between podcast. Host Chris O'Brien welcomes Yochi Slonim, Co-Founder and CEO at .

Listen in to this new episode today! Find it on your favorite streaming platform or visit >> https://bit.ly/FewandFarBetween

Can AI see and talk to human cells? Find out in today's episode of the Biorasi Few & Far Between podcast.Host Chris O'Br...
09/17/2025

Can AI see and talk to human cells? Find out in today's episode of the Biorasi Few & Far Between podcast.

Host Chris O'Brien welcomes Yochi Slonim, Co-Founder and CEO at , to the podcast. Get ready for part two of this special two-part episode as we touch on smarter , evolved agents, and connecting data to real-world biology.

Listen in to this new episode today! Find it on your favorite streaming platform or visit >> https://bit.ly/FewandFarBetween

Face to face at in San Diego!Kick off the event with our PRE-OCT Cocktail Mixer. RSVP by reaching out to Biorasi via F...
09/17/2025

Face to face at in San Diego!

Kick off the event with our PRE-OCT Cocktail Mixer.

RSVP by reaching out to Biorasi via Facebook or contact us at >> https://bit.ly/ContactBiorasiToday

Hello, Princeton! Hello !Sara Vaidya and Robert Royall will be at Booth 4b on Wednesday and Thursday to answer your que...
09/16/2025

Hello, Princeton! Hello !

Sara Vaidya and Robert Royall will be at Booth 4b on Wednesday and Thursday to answer your questions about data sciences - from to study rescue and recovery.

Connect with the Biorasi team before the event >> https://bit.ly/ContactBiorasiToday

Tune in tomorrow for part 2 of a special 2-part episode of the Biorasi Few & Far Between podcast!Host Chris O'Brien wecl...
09/16/2025

Tune in tomorrow for part 2 of a special 2-part episode of the Biorasi Few & Far Between podcast!

Host Chris O'Brien weclomes Yochi Slonim, Co-Founder and CEO of . Join us as we spotlight building a smarter and what might be the missing link to evolution.

09/10/2025

"Let's visualize the highways between the healthy cells and the diseased cells."

Can reveal the inner processes of the human cell? Find out in our latest episode of the Biorasi Few & Far Between podcast. Host Chris O'Brien welcomes Yochi Slonim, Co-Founder and CEO at .

Listen in to this new episode today! Find it on your favorite streaming platform or visit >> https://bit.ly/FewandFarBetween

Address

9505 Biscayne Boulevard , Ste. 2350
Aventura, FL
33180

Opening Hours

Monday 8:30am - 6pm
Tuesday 8:30am - 6pm
Wednesday 8:30am - 6pm
Thursday 8:30am - 6pm
Friday 8:30am - 6pm

Telephone

+17863880700

Website

Alerts

Be the first to know and let us send you an email when Biorasi posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Biorasi:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Our Story

Biorasi is an award-winning full service, global Clinical Research Optimized™ (CRO). From project design to ex*****on success, optimization is engrained in TALOS™. An integrated platform of high performance systems, tools, and processes. By developing and implementing groundbreaking methods of optimizing clinical research, we contribute to enhancement of health and well-being for people around the world. Powered by TALOS™, Biorasi’s full service project teams have developed numerous drugs, biologics and devices that received FDA and multi-venue approvals. Biorasi is headquartered in Miami, FL and has regional operations around the world. Biorasi accelerates the process of obtaining approvals with a full spectrum of services, including: Program Optimization Project Management Regulatory Guidance Clinical Management Data Management & Analysis Compliance & Audit Biorasi is headquartered in Miami, FL and has regional offices across the U.S., Europe, and Asia.